Angelice Alexander-Martin, MD
Addiction Medicine · Columbus, OHNPI 1427150424
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 81.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $3,311 and has fallen 97.2% since, to $91 in 2025.
Across 71 payments — averaging $56.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$3K
- Novo Nordisk$150
- Boston Scientific$145
- Braeburn Inc.$128
- Orexo US, Inc.$120
- Currax Pharmaceuticals LLC$72
- plus $130 from 6 others
What the payments were for
- Speaking & faculty fees$1,95049%
- Travel & lodging$79720%
- Food & beverage$1,21330%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 26 | $3,258 |
| Novo Nordisk | 11 | $150 |
| Boston Scientific | 4 | $145 |
| Braeburn Inc. | 8 | $128 |
| Orexo US, Inc. | 9 | $120 |
| Currax Pharmaceuticals LLC | 5 | $72 |
| Hikma Pharmaceuticals USA | 3 | $56 |
| Medline Industries LP | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Alkermes, Inc. | 1 | $12 |
| Quidel Corporation | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,003 in reported general payments places this provider in the 85th percentile of 98 addiction medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 13 | $10,429 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 30 | $5,878 |
| ProgesteroneProgesterone, Micronized | 14 | $224 |
| Gabapentin | 13 | $30 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Orexo US, Inc.Zubsolv | $120 | $10,42913 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $56 | $5,87830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 98 addiction medicine providers in Ohio.
Other addiction medicine in Columbus
- Stephanie TraylorColumbus$86K
- Orman HallColumbus$10K
- Robert MasoneColumbus$6K
- Roger GarciaColumbus$3K
- Kevin DonlonColumbus$717
- Michael BournColumbus$699
- Larry EverhartColumbus$687
- Thomas NguyenColumbus$569
- Bryan BorlandColumbus$397
- Robert GraessleColumbus$378
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.